Social Media Ideas for Argx

argenx SE (ARGX) Forte Biosciences, Inc. - M&A Call - Slideshow

argenx: Upgrading To Buy, The VYVGART Growth Cycle Has Further To Go

Argenx SE (ARGX) Prepares to Demonstrate Vyvgart’s Efficacy in Broader Autoimmune Diseases

argenx SE (ARGX) Won Its Phase 3 Myositis Trial. How Much Does the Subgroup Miss Matter?

<![CDATA[argenx Acquires Forte Biosciences for $2.2 Billion]]>

Argenx jumps on Phase 3 data for blockbuster Vyvgart

The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments. 

Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug

The deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among multiple developers.

Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)

ARDX closed at $4.00 on August 7, 2026 -- down 17.86% -- after Q2 product revenue of $118.1 million came in below consensus and analysts cut price targets in accord.

Argan: Solid Visibility And Disciplined Execution Still Justifies A Buy

Sales expansion

Sales expansion Anonymous (not verified) Tue, 09/08/2026 - 15:50 field_thread_url https://cafepharma.com/boards/threads/sales-expansion.695083/...

Arcus: 'Buy' On Casdatifan Late-Stage CcRCC Advancement And 1st-Line Expansions

AGC and Neusignal Therapeutics Collaborate on the Development of Alzheimer's Disease Drug Candidate “NTX-083”

AGC Inc. (Headquarters: Tokyo; President: Yoshinori Hirai; hereinafter “AGC”) highlights its end-to-end support capabilities as a small-molecule pharmaceutical CDMO as demonstrated...

Argo Graphene amends $1 million financing, advances STREAM graphene commercialization

Argo Graphene Solutions Corp. (CSE: ARGO), developer of the STREAMâ„¢ graphene production platform, has amended the terms of the non-brokered private placement it announced earlier...

ARS Pharma: New CEO's Program Of Reducing Costs While Increasing Revenues Makes A Buy

Argenx’s $2B Forte Bio Acquisition Brings Autoimmune Playbook to Prevalent Disorders

Argenx’s first acquisition is the buyout of Forte Biosciences, a company with a lead drug that has early clinical validation in celiac disease and vitiligo. Argenx executives say t...

Forte Biosciences shares jump after $2.2 billion takeover agreement with argenx

Argan Has Had A Great Run, But Further Upside Will Be Harder From Here (Downgrade)

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between Marc...

Argan: Strong Growth, But The Current Valuation Limits Its Potential

Archer Limited (ARHVF) Q2 2026 Earnings Call Prepared Remarks Transcript

ARYZTA AG (ARZTY) Q2 2026 Earnings Call Transcript

Antero Resources Corporation (AR) Q2 2026 Earnings Call Transcript

AMG River Road Dividend All Cap Value Fund Q2 2026 Commentary

ARS Pharmaceuticals, Inc. (SPRY) Q2 2026 Earnings Call Transcript